Werfel, Stanislas
Lorenz, Georg
Haller, Bernhard
Günthner, Roman
Matschkal, Julia
Braunisch, Matthias C.
Schaller, Carolin
Gundel, Peter
Kemmner, Stephan
Hayek, Salim S.
Nusshag, Christian
Reiser, Jochen
Moog, Philipp
Heemann, Uwe
Schmaderer, Christoph
Funding for this research was provided by:
Baxter International (IIR grant)
Else-Kröner-Fresenius Foundation (P27/10//A33/10)
Technische Universität München
Article History
Received: 27 June 2020
Accepted: 9 April 2021
First Online: 29 April 2021
Competing interests
: J. Reiser reports grants from National Institute of Health, Thermo BCT and Nephcure, personal fees from Biomarin, TRISAQ, Astellas, Massachusetts General Hospital, Genentech, Up to Date, Merck, Inceptionsci, GLG, Clearview, outside the submitted work; In addition, J. Reiser reports patents licensed to Miltenyi and TRISAQ, outside the submitted work. J. Reiser reports he is co-founder and share holder of TRISAQ, a bio-pharmaceutical company that develops drugs for kidney disease. All of the remaining authors have nothing to disclose.